Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$40.68

-1.86 (-4.37%)

, AZN

AstraZeneca

$35.42

0.07 (0.20%)

07:12
04/09/18
04/09
07:12
04/09/18
07:12

Ionis Pharmaceuticals, AstraZeneca advance new drug for NASH

Ionis Pharmaceuticals (IONS) announced that it has licensed IONIS-AZ6-2.5-L, or AZD2693, to AstraZeneca (AZN) following advancement of the drug into development. IONIS-AZ6-2.5-L is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis. In conjunction with this milestone, global, AstraZeneca will pay a $30M license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-L. As IONIS-AZ6-2.5-L advances in development, Ionis may also receive up to $300M in additional development and regulatory milestone payments, as well as tiered royalties up to the low teens from sales of the drug.

IONS

Ionis Pharmaceuticals

$40.68

-1.86 (-4.37%)

AZN

AstraZeneca

$35.42

0.07 (0.20%)

  • 14

    Apr

  • 23

    Apr

  • 23

    May

  • 06

    Jul

IONS Ionis Pharmaceuticals
$40.68

-1.86 (-4.37%)

02/20/18
BERN
02/20/18
NO CHANGE
Target $55
BERN
Market Perform
Ionis Pharmaceuticals price target lowered to $55 from $61 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Ionis Pharmaceuticals to $55 from $61 reflecting what is likely to be a faster decline in Spinraza sales trajectory than he had previously modeled. The analyst reiterates a Market Perform rating on the shares.
03/15/18
03/15/18
UPGRADE
Target $30

Outperform
Akcea Therapeutics upgraded to Outperform at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Akcea Therapeutics (AKCA) to Outperform from Market Perform following the collaboration agreement with Ionis Pharmaceuticals (IONS) for antisense oligonucleotide therapeutic inotersen for TTR amyloidosis. The analyst also raised his price target on Akcea's shares to $30 from $20.
03/15/18
RILY
03/15/18
NO CHANGE
Target $200
RILY
Buy
Ionis not finding external partner positive for Alnylam, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar says Ionis Pharmaceuticals' (IONS) inability to find an external partner for the commercial development of inotersen is a "material positive" for Alnylam Pharmaceuticals (ALNY) and its lead asset patisiran. He believes "middling efficacy, safety concerns, and IP risks" likely prevented an external partner from being interested in inotersen. The analyst keeps a Buy rating on Alnylam with a $200 price target.
03/16/18
STFL
03/16/18
NO CHANGE
Target $30
STFL
Hold
Inotersen licensing deal changes narrative for Akcea, says Stifel
Stifel analyst Stephen Willey believes Akcea Therapeutics' (AKCA) inotersen licensing deal with Ionis Pharmaceuticals (IONS) changes both the near and longer-term narrative for Akcea, as it diversifies both the revenue base and product pipeline and provides "a layer of insulation" from any potential volanesorsen-related volatility that may emerge from the Advisory Committee meeting coming on May 10. Willey raised his price target on Akcea to $30 from $20, but keeps a Hold rating on the stock, stating that he'd look to be more constructive if any near-term volanesorsen-related weakness occurs.
AZN AstraZeneca
$35.42

0.07 (0.20%)

03/14/18
HCWC
03/14/18
NO CHANGE
Target $6
HCWC
Buy
Advaxis drug unlikely culprit of patient death, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Advaxis (ADXS) to $6 from $23 after the FDA placed a clinical hold on the Phase 1/2 study investigating the combination of the company's axalimogene filolisbac and AstraZeneca's (AZN) durvalumab for the treatment of HPV-associated cervical and head and neck cancers. Based on its previous safety profile, axalimogene is unlikely to be the cause of death for this patient, Ramakanth tells investors in a research note. The analyst, however, notes that it would likely take several months before the FDA is able to reach a decision and lift the clinical hold. He anticipates a one-to-two quarter delay to the axal plus durva combination therapy program but keeps a Buy rating on Advaxis shares.
03/19/18
JEFF
03/19/18
UPGRADE
JEFF
Buy
AstraZeneca upgraded to Buy from Hold at Jefferies
Jefferies analyst Ian Hilliker upgraded AstraZeneca to Buy and raised his price target for the shares to 5,600p from 5,075p. The company is at a "turning point," Hilliker tells investors in a research note. He believes accelerating new product launches and improving margins should deliver over 20% core earnings growth in the mid-term. Recovering growth, driven by the underlying business warrants a "modest mid-term premium valuation," the analyst contends.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/18
PIPR
04/06/18
NO CHANGE
PIPR
Neutral
Clovis approval underscores rising competition facing Zejula, says Piper Jaffray
Prior to today's announcement that Clovis' (CLVS) label for its PARP inhibitor Rubraca has been expanded to include maintenance therapy in ovarian cancer, AstraZeneca's (AZN) Lynparza and Tesaro's (TSRO) Zejula were the only two PARP inhibitors approved in the maintenance setting, noted Piper Jaffray analyst Christopher Raymond. While Clovis' approval is not a surprise, it does underscore the intensifying competitive pressure facing Zejula, he said. Raymond, who said PARP inhibitors will primarily be differentiated on safety and added that this does not favor Zejula, keeps a Neutral rating on Tesaro.

TODAY'S FREE FLY STORIES

FB

Facebook

$159.66

-6.19 (-3.73%)

20:37
04/24/18
04/24
20:37
04/24/18
20:37
Periodicals
Facebook replaces Erin Egan, the head of policy for U.S., NYT reports »

Fecebook head of U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BOOT

Boot Barn

$19.76

0.305 (1.57%)

20:33
04/24/18
04/24
20:33
04/24/18
20:33
Hot Stocks
Boot Barn acquires Lone Star Western & Casual LLC assets, terms not disclosed »

Boot Barn Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$329.00

-9.52 (-2.81%)

, CMCSA

Comcast

$33.33

-0.53 (-1.57%)

20:25
04/24/18
04/24
20:25
04/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$329.00

-9.52 (-2.81%)

CMCSA

Comcast

$33.33

-0.53 (-1.57%)

CMCSK

Comcast

TMO

Thermo Fisher

$213.13

-3.17 (-1.47%)

GD

General Dynamics

$222.04

-4.05 (-1.79%)

NOC

Northrop Grumman

$341.00

-15.06 (-4.23%)

ANTM

Anthem

$225.08

-2.11 (-0.93%)

NSC

Norfolk Southern

$134.92

-2.83 (-2.05%)

BSX

Boston Scientific

$28.43

-0.39 (-1.35%)

SIRI

SiriusXM

$6.27

-0.06 (-0.95%)

TROW

T. Rowe Price

$107.42

-1.23 (-1.13%)

TWTR

Twitter

$30.48

-0.74 (-2.37%)

ROK

Rockwell Automation

$161.97

-7.185 (-4.25%)

DPS

Dr Pepper Snapple

$118.87

-1 (-0.83%)

STM

STMicroelectronics

$21.30

0.35 (1.67%)

HES

Hess Corp.

$57.71

-0.83 (-1.42%)

NDAQ

Nasdaq

$86.27

-0.65 (-0.75%)

VIAB

Viacom

$30.91

-0.14 (-0.45%)

OC

Owens Corning

$75.79

-2.32 (-2.97%)

GT

Goodyear Tire

$26.86

-0.14 (-0.52%)

NYCB

New York Community Bancorp

$12.97

0.115 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 07

    May

  • 18

    May

  • 22

    May

  • 29

    May

  • 30

    May

  • 30

    May

FBMS

First Bancshares

$31.90

-0.1 (-0.31%)

20:18
04/24/18
04/24
20:18
04/24/18
20:18
Earnings
First Bancshares reports Q1 adjusted EPS 46c, consensus 48c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

NVS

Novartis

$77.00

-0.595 (-0.77%)

, GILD

Gilead

$72.71

-1.27 (-1.72%)

20:03
04/24/18
04/24
20:03
04/24/18
20:03
Periodicals
CAR-T blood cancer treatments may be Medicare-eligible, Bloomberg says »

Customized blood cancer…

NVS

Novartis

$77.00

-0.595 (-0.77%)

GILD

Gilead

$72.71

-1.27 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 05

    Jun

LPL

LG Display

$11.19

-0.21 (-1.84%)

19:50
04/24/18
04/24
19:50
04/24/18
19:50
Earnings
LG Display reports Q1 Net loss KRW 49B vs. net profit KRW 679B last year »

Reports Q1 revenue KRW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$80.09

-0.16 (-0.20%)

, CG

Carlyle Group

$20.65

-0.35 (-1.67%)

19:45
04/24/18
04/24
19:45
04/24/18
19:45
Periodicals
Eli Lilly animal health business seeing private equity interest, Bloomberg says »

Bain Capital, Advent…

LLY

Eli Lilly

$80.09

-0.16 (-0.20%)

CG

Carlyle Group

$20.65

-0.35 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 07

    May

  • 21

    May

  • 07

    Jun

  • 07

    Jun

DOC

Physicians Realty Trust

$14.67

0.185 (1.28%)

19:40
04/24/18
04/24
19:40
04/24/18
19:40
Downgrade
Physicians Realty Trust rating change  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

LFC

China Life Insurance

19:38
04/24/18
04/24
19:38
04/24/18
19:38
Upgrade
China Life Insurance rating change  »

China Life Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

19:37
04/24/18
04/24
19:37
04/24/18
19:37
Downgrade
Healthcare Trust rating change  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

HR

Healthcare Realty Trust

$27.10

0.325 (1.21%)

19:37
04/24/18
04/24
19:37
04/24/18
19:37
Downgrade
Healthcare Realty Trust rating change  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

GOOGL

Alphabet Class A

$1,022.98

-50.08 (-4.67%)

19:37
04/24/18
04/24
19:37
04/24/18
19:37
Upgrade
Alphabet Class A rating change  »

Alphabet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$35.00

0.11 (0.32%)

, TWX

Time Warner

$96.02

-0.32 (-0.33%)

19:25
04/24/18
04/24
19:25
04/24/18
19:25
Periodicals
AT&T lawyer grills star U.S. witness over data in pay-TV study, Bloomberg says »

The U.S.…

T

AT&T

$35.00

0.11 (0.32%)

TWX

Time Warner

$96.02

-0.32 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

SHPG

Shire

$164.05

3.97 (2.48%)

, TKPYY

Takeda Pharmaceutical

19:15
04/24/18
04/24
19:15
04/24/18
19:15
Hot Stocks
Shire confirms receipt of revised GBP46B stock and cash proposal from Takeda »

The board of Shire (SHPG)…

SHPG

Shire

$164.05

3.97 (2.48%)

TKPYY

Takeda Pharmaceutical

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

CREE

Cree

$39.39

-1 (-2.48%)

, SIX

Six Flags

$59.17

-1.62 (-2.66%)

19:02
04/24/18
04/24
19:02
04/24/18
19:02
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Cree…

CREE

Cree

$39.39

-1 (-2.48%)

SIX

Six Flags

$59.17

-1.62 (-2.66%)

TXN

Texas Instruments

$98.33

0.25 (0.25%)

USNA

USANA

$95.93

0.175 (0.18%)

MKSI

MKS Instruments

$102.85

-3.35 (-3.15%)

SVU

Supervalu

$14.61

-0.02 (-0.14%)

IRBT

iRobot

$59.10

-0.85 (-1.42%)

DDR

DDR Corp.

$6.68

0.025 (0.38%)

IPHI

Inphi

$31.46

1.1 (3.62%)

HA

Hawaiian Holdings

$39.20

-0.3 (-0.76%)

SHPG

Shire

$164.05

3.97 (2.48%)

KN

Knowles

$11.01

-0.575 (-4.97%)

TER

Teradyne

$41.50

1.06 (2.62%)

EW

Edwards Lifesciences

$134.63

-2.59 (-1.89%)

DLB

Dolby

$65.85

-1.4 (-2.08%)

WYNN

Wynn Resorts

$189.70

-3.54 (-1.83%)

COF

Capital One

$97.41

-0.115 (-0.12%)

SGMO

Sangamo

$17.85

-0.3 (-1.65%)

MRTX

Mirati Therapeutics

$28.25

-0.15 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 03

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 23

    May

  • 29

    May

  • 30

    May

  • 12

    Jun

  • 14

    Aug

  • 21

    Dec

  • 26

    Apr

AMX

America Movil, also tag AMOV

$18.62

-0.15 (-0.80%)

, AMOV

America Movil, also tag AMX

$18.50

-0.27 (-1.44%)

19:02
04/24/18
04/24
19:02
04/24/18
19:02
Earnings
America Movil reports Q1 net profit MXN18.1B vs. MXN35.9B last year »

Reports Q1 revenue…

AMX

America Movil, also tag AMOV

$18.62

-0.15 (-0.80%)

AMOV

America Movil, also tag AMX

$18.50

-0.27 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEP

American Electric

$68.89

0.46 (0.67%)

, WMT

Walmart

$86.51

0.41 (0.48%)

18:30
04/24/18
04/24
18:30
04/24/18
18:30
Hot Stocks
PSO, OEIC, Walmart reach settlement pact on proposed Wind Catcher project »

Public Service Company of…

AEP

American Electric

$68.89

0.46 (0.67%)

WMT

Walmart

$86.51

0.41 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

  • 15

    May

  • 17

    May

  • 30

    May

  • 01

    Jun

AMGN

Amgen

$171.91

-2.75 (-1.57%)

18:05
04/24/18
04/24
18:05
04/24/18
18:05
Hot Stocks
Breaking Hot Stocks news story on Amgen »

Amgen reports Q1 Repatha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 22

    May

  • 28

    May

AMGN

Amgen

$171.91

-2.75 (-1.57%)

18:03
04/24/18
04/24
18:03
04/24/18
18:03
Hot Stocks
Amgen CEO says Q1 performance driven by new, recently launched products »

"Amgen's strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 22

    May

  • 28

    May

NWE

NorthWestern

$54.36

0.315 (0.58%)

18:03
04/24/18
04/24
18:03
04/24/18
18:03
Earnings
Breaking Earnings news story on NorthWestern »

NorthWestern reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 20

    May

NWE

NorthWestern

$54.36

0.315 (0.58%)

18:01
04/24/18
04/24
18:01
04/24/18
18:01
Earnings
NorthWestern reports Q1 EPS $1.18, consensus $1.17 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 20

    May

FR

First Industrial Realty

$29.62

0.315 (1.07%)

18:00
04/24/18
04/24
18:00
04/24/18
18:00
Earnings
First Industrial Realty reports Q1 FFO 38c, consensus 38c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

NVT

nVent Electric

, KN

Knowles

$11.01

-0.575 (-4.97%)

17:59
04/24/18
04/24
17:59
04/24/18
17:59
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

nVent Electric (NVT) will…

NVT

nVent Electric

KN

Knowles

$11.01

-0.575 (-4.97%)

DHX

DHI Group

PNR

Pentair

$67.14

-2.13 (-3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    May

  • 08

    May

  • 29

    May

VICR

Vicor Corporation

$29.25

-0.6 (-2.01%)

17:57
04/24/18
04/24
17:57
04/24/18
17:57
Earnings
Vicor reports Q1 EPS 10c vs.(2c) in same quarter last year »

Vicor reports Q1 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SMBK

SmartFinancial

17:53
04/24/18
04/24
17:53
04/24/18
17:53
Earnings
SmartFinancial reports Q1 EPS 30c, consensus 34c »

Billy Carroll, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    Jun

  • 24

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.